CA2356124A1 - Anti-ige vaccines - Google Patents

Anti-ige vaccines Download PDF

Info

Publication number
CA2356124A1
CA2356124A1 CA002356124A CA2356124A CA2356124A1 CA 2356124 A1 CA2356124 A1 CA 2356124A1 CA 002356124 A CA002356124 A CA 002356124A CA 2356124 A CA2356124 A CA 2356124A CA 2356124 A1 CA2356124 A1 CA 2356124A1
Authority
CA
Canada
Prior art keywords
seq
ige
amino acid
antigenic
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002356124A
Other languages
English (en)
French (fr)
Inventor
Mohamad Ali Morsey
Michael George Sheppard
David Walter Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis P LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002674888A priority Critical patent/CA2674888A1/en
Priority to CA2674837A priority patent/CA2674837C/en
Priority to CA2674885A priority patent/CA2674885C/en
Priority to CA2674838A priority patent/CA2674838C/en
Publication of CA2356124A1 publication Critical patent/CA2356124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA002356124A 2000-08-30 2001-08-28 Anti-ige vaccines Abandoned CA2356124A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002674888A CA2674888A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674837A CA2674837C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674885A CA2674885C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674838A CA2674838C (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22898900P 2000-08-30 2000-08-30
US60/228,989 2000-08-30

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CA2674838A Division CA2674838C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674837A Division CA2674837C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA002674888A Division CA2674888A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674885A Division CA2674885C (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Publications (1)

Publication Number Publication Date
CA2356124A1 true CA2356124A1 (en) 2002-02-28

Family

ID=22859366

Family Applications (5)

Application Number Title Priority Date Filing Date
CA002356124A Abandoned CA2356124A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674885A Expired - Fee Related CA2674885C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674837A Expired - Fee Related CA2674837C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674838A Expired - Fee Related CA2674838C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA002674888A Abandoned CA2674888A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA2674885A Expired - Fee Related CA2674885C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674837A Expired - Fee Related CA2674837C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA2674838A Expired - Fee Related CA2674838C (en) 2000-08-30 2001-08-28 Anti-ige vaccines
CA002674888A Abandoned CA2674888A1 (en) 2000-08-30 2001-08-28 Anti-ige vaccines

Country Status (4)

Country Link
US (5) US6887472B2 (enExample)
EP (5) EP2065052A3 (enExample)
JP (5) JP2002281984A (enExample)
CA (5) CA2356124A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
ATE438710T1 (de) * 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
ES2316780T3 (es) * 2002-09-05 2009-04-16 Resistentia Pharmaceuticals Ab Vacunas contra alergia.
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP2008507474A (ja) 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定
JP4520923B2 (ja) * 2005-09-28 2010-08-11 本田技研工業株式会社 エンジン始動装置
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
AU2013204233B2 (en) * 2008-12-09 2015-06-25 Pfizer Vaccines Llc IgE CH3 peptide vaccine
BRPI0922561A2 (pt) * 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
DK2401300T3 (en) * 2009-02-25 2018-04-23 Academia Sinica ANTI-C [epsilon] mX antibodies capable of binding to human gut on B lymphocytes
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
KR101163472B1 (ko) * 2010-06-08 2012-07-18 기아자동차주식회사 자동차의 오프닝 웨더스트립 고정구조
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013158274A1 (en) 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
CN102660569B (zh) * 2012-04-21 2013-11-06 大连理工大学 一种重组人IgE受体蛋白的制备方法及应用
CN104395337A (zh) 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
EP3156423B1 (en) * 2014-06-11 2025-02-19 Riken Multiplex alloantigenic peptide
JP6878301B2 (ja) * 2015-04-09 2021-05-26 コーネル ユニヴァーシティー アレルゲンに対する反応を予防するための遺伝子治療
EP3703753A4 (en) 2017-10-31 2021-08-18 Oneness Biotech Co., Ltd. TREATMENT OF ALLERGIC DISEASES MEDIA BY IGE
US11857623B2 (en) * 2020-08-07 2024-01-02 King Abdulaziz University Pan-antiallergy vaccine
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN115873867B (zh) * 2022-09-28 2023-06-23 云南省农业科学院农业环境资源研究所 一种抗稻瘟病基因Pi69及其编码蛋白与应用
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN118878689B (zh) * 2024-08-28 2025-03-28 上海索莱宝生化科技有限公司 抗猪IgG抗体及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5668615A (en) 1979-11-09 1981-06-09 Eisai Co Ltd Ricin-containing agent for immunological enhancement
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
JPS63225397A (ja) 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
WO1992020316A2 (en) 1991-05-14 1992-11-26 University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
EP0586532A4 (en) * 1991-05-24 1994-08-17 Univ Northwestern Method of using substance p to treat allergy
DK0587738T3 (da) 1991-06-05 2000-12-18 Univ Connecticut Destineret levering af gener, som koder for sekretionsproteiner
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
US5629415A (en) * 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
JPH09169795A (ja) * 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
WO1997030156A2 (en) 1996-02-14 1997-08-21 Idexx Laboratories, Inc. NUCLEOTIDES AND PEPTIDES CORRESPONDING TO THE CANINE IgE HEAVY CHAIN CONSTANT REGION AND RELATED METHODS
TR199801722T2 (xx) 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
ES2165626T3 (es) 1996-08-30 2002-03-16 Exxonmobil Chem Patents Inc Reactor y procedimiento en lecho fluidizado.
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
ES2234180T3 (es) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. Proteinas de fijacion especifica para el tratamiento de la alergia canina.
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
CN1189749C (zh) * 1998-06-24 2005-02-16 阿尔克-阿贝洛有限公司 检测液体样品中抗体的方法
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CN1202125C (zh) * 1998-11-12 2005-05-18 卫生部上海生物制品研究所 肽免疫原、用其制成的治疗变态反应的疫苗及其制备方法
EP2065052A3 (en) 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン

Also Published As

Publication number Publication date
US20040146504A1 (en) 2004-07-29
JP2005043374A (ja) 2005-02-17
EP1195161A3 (en) 2002-07-24
EP1195161A2 (en) 2002-04-10
EP1967205B1 (en) 2012-10-10
EP2361635A3 (en) 2011-09-14
EP2065052A3 (en) 2009-08-19
CA2674838A1 (en) 2002-02-28
US20020064525A1 (en) 2002-05-30
JP2005102701A (ja) 2005-04-21
US7897151B2 (en) 2011-03-01
US20120321651A1 (en) 2012-12-20
US8273356B2 (en) 2012-09-25
JP2002281984A (ja) 2002-10-02
EP2065052A2 (en) 2009-06-03
EP1967206A3 (en) 2009-01-07
JP2012161322A (ja) 2012-08-30
CA2674885A1 (en) 2002-02-28
JP2013056904A (ja) 2013-03-28
US20100113361A1 (en) 2010-05-06
EP1967205A2 (en) 2008-09-10
EP1967206B1 (en) 2012-10-10
CA2674837C (en) 2013-02-26
EP1967205A3 (en) 2009-01-07
US6887472B2 (en) 2005-05-03
CA2674837A1 (en) 2002-02-28
CA2674885C (en) 2013-02-26
US20060062782A1 (en) 2006-03-23
CA2674838C (en) 2014-02-18
EP1967206A2 (en) 2008-09-10
EP2361635A2 (en) 2011-08-31
CA2674888A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
US8273356B2 (en) Anti-IgE vaccines
US20080193439A1 (en) Non-Anaphylactogenic IgE Fusion Proteins
EP0666760B2 (en) VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS
TW201038284A (en) Treatment of insulin-resistant disorders
CN102702359A (zh) 新的IgE表位的鉴别
JP2000502995A (ja) Ｂリンパ球による抗体放出を刺激する組成物および方法
AU753753B2 (en) Contraceptive antibody vaccines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140905